{
    "clinical_study": {
        "@rank": "129280", 
        "acronym": "IRETB", 
        "arm_group": [
            {
                "arm_group_label": "vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)", 
                "arm_group_type": "Active Comparator", 
                "description": "Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks."
            }, 
            {
                "arm_group_label": "Placebo tablets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim with study is to provide adjunctive therapy with vitamin D and phenylbutyrate\n      together with standard anti-tuberculosis treatment to significantly improve clinical\n      recovery among patients with untreated, active pulmonary tuberculosis."
        }, 
        "brief_title": "Immune Reconstitution in Tuberculosis Disease", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Tuberculosis (TB)", 
        "condition_browse": {
            "mesh_term": [
                "Tuberculosis", 
                "Tuberculosis, Pulmonary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        HIV negative patients, adult patients >18 years who has not started anti-TB therapy.\n\n        Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputum-negative\n        clinical TB cases (defined according to the WHO 2006 criteria for sputum smear-negative TB\n        ie. clinical symptoms of TB, chest X-ray findings and response to standard treatment).\n\n        Exclusion Criteria:\n\n        Patients who have already started treatment with anti-TB drugs for more that 5 days.\n\n        HIV-positive patients.\n\n        History of anti-TB treatment in the past 2 years.\n\n        Local extra-pulmonary TB in the absence of lung manifestations.\n\n        Hypercalcaemia (serum calcium > 2.6 mmol/L) identified at baseline.\n\n        Pregnant and breast feeding women.\n\n        Any known liver or kidney function abnormality, malignancy or patients treated with\n        cardiac glycosides."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698476", 
            "org_study_id": "IRETB-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)", 
                "description": "Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.", 
                "intervention_name": "vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo tablets", 
                "intervention_name": "Placebo tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "4-phenylbutyric acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pulmonary TB", 
            "cholecalciferol", 
            "sodium phenylbutyrate", 
            "antimicrobial peptides", 
            "immune response"
        ], 
        "lastchanged_date": "October 2, 2012", 
        "location": {
            "contact": {
                "email": "endalekassalulu@gmail.com", 
                "last_name": "Endale Kassa, MD", 
                "phone": "251-911228562"
            }, 
            "facility": {
                "address": {
                    "city": "Addis Ababa", 
                    "country": "Ethiopia", 
                    "state": "Lideta sub city"
                }, 
                "name": "Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine"
            }, 
            "investigator": {
                "last_name": "Endale Kassa, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Ethiopia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Immune Reconstitution in Tuberculosis Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate", 
        "other_outcome": {
            "description": "An interim analysis will be performed after approx. 100-150 patients have been included into the study.", 
            "measure": "Interim analysis", 
            "safety_issue": "Yes"
        }, 
        "overall_contact": {
            "email": "endalekassalulu@gmail.com", 
            "last_name": "Endale Kassa, MD", 
            "phone": "251-911228562"
        }, 
        "overall_contact_backup": {
            "email": "wonamogne@yahoo.com", 
            "last_name": "Wondwossen Amogne, MD", 
            "phone": "251-911406179"
        }, 
        "overall_official": {
            "affiliation": "Karolinska Institutet", 
            "last_name": "Susanna Brighenti, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ethiopia: Food, Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A previously described composite clinical TB score will be used to monitor the efficacy of vitamin D and phenylbutyrate treatment among TB patients on standard chemotherapy. The numerical TB score will include self-reported clinical symptoms (cough, night sweats and chest pain) as well as different parameters determined upon clinical examination anemia/conjunctival pallor, haemoptysis, dyspnoea, tachycardia, positive finding at lung auscultation, fever, low body mass index (BMI) and low mid upper arm circumference (MUAC). The TB score will be determined at the time of diagnosis (time point 0) and at 4, 8, 16 and 24 weeks after initiation of antimicrobial treatment with vitamin D and phenylbutyrate. The primary endpoint will be assessed at time point 8 weeks compared to baseline (time point 0).", 
            "measure": "Composite clinical TB score", 
            "safety_issue": "Yes", 
            "time_frame": "0 (baseline) compared to 8 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698476"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska Institutet", 
            "investigator_full_name": "Susanna Brighenti", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical composite TB score (0, 4, 16, 24 weeks).\nModified clinical composite TB score (0, 4, 8, 16, 24 weeks).\nChest X-ray (0, 4, 8, 16, 24 weeks).\nTime to sputum- and/or TB culture conversion (0, 1, 2, 3, 4, 8 weeks).", 
                "measure": "Clinical secondary endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "0-4, 8, 16 and 24 weeks"
            }, 
            {
                "description": "Peripheral CD4/CD8 T cell counts.\nAntibodies in lymphocytes secertions (ALS) (S Ashenafi, Thorax, 2012).\nQuantiferon-in-tube TB-gold (QFT).\nPlasma levels of vitamin D, LL-37 and also cytokine/chemokine profiles.\nFunctional studies of immune cells (PBMCs).", 
                "measure": "Laboratory secondary endpoints", 
                "safety_issue": "No", 
                "time_frame": "0, 4, 8, 16, 24 weeks"
            }
        ], 
        "source": "Karolinska Institutet", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Addis Ababa University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Karolinska Institutet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}